173 related articles for article (PubMed ID: 31869655)
1. Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
Yang H; Yan R; Jiang Y; Yang Z; Zhang X; Zhou M; Wu X; Zhang T; Zhang J
Eur J Med Chem; 2020 Feb; 187():111966. PubMed ID: 31869655
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors.
Li Y; Chang Y; Fu J; Ding R; Zhang L; Liang T; Liu Y; Liu Y; Hu J
Eur J Med Chem; 2021 Dec; 226():113845. PubMed ID: 34534838
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
Zhang B; Liu Z; Xia S; Liu Q; Gou S
Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
[TBL] [Abstract][Full Text] [Related]
11. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
12. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
13. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.
Huang J; Huang J; Wang N; Wang L; Li L; Wang C; Sun X; Li Y; Huang G; Ma X
Bioorg Chem; 2019 Aug; 89():102994. PubMed ID: 31185393
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC.
Chen L; Zhang Y; Wang C; Tang Z; Meng Q; Sun H; Qi Y; Ma X; Li L; Li Y; Xu Y
Bioorg Chem; 2021 Sep; 114():105045. PubMed ID: 34161879
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
Das D; Xie L; Wang J; Shi J; Hong J
Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
20. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
